Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30396142 | 1.00 | DDB1 (0.46) | DDB1CRBNGPR119RORCKDM4E | |
| SCHEMBL22059965 | 0.90 | RORC (0.46) | DDB1CRBNGPR119RORCKDM4E | |
| SCHEMBL31639929 | 0.85 | DDB1 (0.47) | DDB1CRBNGPR119RORCKDM4E | |
| SCHEMBL30395072 | 0.84 | DDB1 (0.46) | DDB1CRBNGPR119RORCKDM4E | |
| SCHEMBL20757383 | 0.84 | DDB1 (0.46) | DDB1CRBNGPR119RORCKDM4E | |
| SCHEMBL29497069 | 0.84 | DDB1 (0.46) | DDB1CRBNGPR119RORCKDM4E | |
| SCHEMBL24989018 | 0.84 | DDB1 (0.46) | DDB1CRBNGPR119RORCKDM4E | |
| SCHEMBL255448 | 0.84 | ALOX5AP (0.47) | DDB1CRBNRORCKDM4EPDE4B | |
| SCHEMBL255458 | 0.84 | DDB1 (0.46) | DDB1CRBNGPR119RORCKDM4E | |
| SCHEMBL30394540 | 0.84 | DDB1 (0.46) | DDB1CRBNGPR119RORCKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| WO-2023247670-A1 | NEW HETEROCYCLIC-CARBONYL-CYCLIC COMPOUNDS AS MAGL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-12-28 | — | — | WO | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| CN-115989228-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | CBR3, BRIX1, CCNY | DDB1 2404/4885CRBN 570/4885GPR119 2316/4885 |
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | DDB1 2404/4885CRBN 570/4885GPR119 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.